Claims

1. An antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein -

(a) the VH domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of:

a CDR1 sequence comprising an amino acid sequence having at least 25%, 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17;

a CDR2 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and

a CDR3 sequence comprising an amino acid sequence having at least 4%, 9%, 13%, 18%, 22%, 27%, 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22; and/or

(b) the VL domain comprises an amino acid sequence that includes one, two or three complementarity determining regions (CDRs) selected from the group consisting of:

a CDR4 sequence comprising an amino acid sequence having at least 5%, 11%, 17%, 23%, 29%, 35%, 47%, 52%, 58%, 64%, 70%, 76%, 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24;

a CDR5 sequence comprising an amino acid sequence having at least 14%, 28%, 42%, 57%, 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25;

a CDR6 sequence comprising an amino acid sequence having at least 11%, 22%, 33%, 44%, 55%, 66%, 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26.

2. The antibody or antibody fragment of Claim 1 wherein the VH domain comprises an amino acid sequence that includes a CDR1 sequence, a CDR2 and a

CDR3 sequence as defined by Claim 1, and/or the VL domain comprises an amino acid sequence that includes a CDR4 sequence, a CDR5 and a CDR6 sequence as defined by Claim 1.

3. The antibody or antibody fragment of Claim 1 or 2 wherein –

the VH domain comprises an amino acid sequence that includes the CDR1, CDR2 and CDR3 sequences present in an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15 or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence of any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15; and/or

the VL domain comprises an amino acid sequence that includes the CDR4, CDR5 and CDR6 sequences present in an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16 or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence of any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16.

4. An antibody or antibody fragment according to any preceding claim, wherein -

the VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15 or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence of any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15; and

the VL domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16 or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence of any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16.

5. The antibody or antibody fragment according to any of the preceding claims, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:1; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 2.

6. The antibody or antibody fragment according to any of Claims 1 to 4, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:3; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 4.

7. The antibody or antibody fragment according to any of Claims 1 to 4, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:5; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 6.

8. The antibody or antibody fragment according to any of Claims 1 to 4, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:7; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 8.

9. The antibody or antibody fragment according to any of Claims 1 to 4, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:9; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 10.

10. The antibody or antibody fragment according to any one of Claims 1 to 4, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:11; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 12.

11. The antibody or antibody fragment according to any one of Claims 1 to 4, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:13; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 14.

12. The antibody or antibody fragment according to any one of Claims 1 to 4, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:15; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 16.

13. The antibody or antibody fragment according to any preceding claim,

wherein the VH domain, the VL domain, or preferably both of the VH and VL domains, comprise an amino acid sequence having 100% sequence identity to the, or one or more (such as all) of each, stated SEQ ID NO.

14. The antibody or antibody fragment according to any preceding claim,

wherein the VH domain, the VL domain, or both of the VH and VL domains, comprise an amino acid sequence having less than 100%, but at least 80%, 85%, 90%, 95%, sequence identity to the, or one or more (such as all) of each, stated SEQ ID NO.

15. The antibody or antibody fragment according to any of preceding claim,

wherein the VH domain, the VL domain, or both of the VH and VL domains, comprise an amino acid sequence having less than 100%, but at least 80%, 85%, 90%, 95% sequence identity to the, or one or more (such as all) of each, stated SEQ ID NO, and wherein

the ability of the antibody or antibody fragment to bind to phosphorylcholine and/or a phosphorylcholine conjugate is equivalent to (that is, at least 80%, 85%, 90% or 95%, of), or greater than, the ability of a corresponding antibody or antibody fragment, wherein the VH domain and the VL domain of the corresponding antibody or antibody fragment each comprise an antigen-binding sequence comprising an amino acid sequence having 100% sequence identity to the, or each, stated SEQ ID NO.

16. The antibody or antibody fragment according to any preceding claim wherein the VH domain and the VL domain are present in a linear polypeptide sequence.

17. The antibody or antibody fragment according to any preceding claim wherein the VH domain and the VL domain are each present in a separate polypeptide sequence, and preferably wherein the separate polypeptide sequence are directly or indirectly bound together (such as by one or more disulphide bonds between the separate polypeptide sequence).

18. The antibody according to any of Claims 1-15 or 17 wherein the antibody is a monoclonal antibody.

19. The antibody fragment according to any of Claims 1 to 15 wherein the antibody fragment is a single chain antibody, Fv, scFv, Fab, $F(ab')_2$, Fab', Fd, dAb, CDR, or scFv-Fc fragment, a nanobody, and diabody, or any such fragment that has been stabilized such as by PEGylation.

20. The antibody or antibody fragment according to any preceding claim which is a human or humanized antibody or antibody fragment, such as a human or humanized monoclonal antibody.

21. The antibody or antibody fragment according to any preceding claim which is capable of binding to a phosphorylcholine conjugate.

22. The antibody or antibody fragment according to Claim 21 wherein the phosphorylcholine conjugate is a phosphorylcholine moiety linked to a carrier, optionally via a spacer, and preferably the antibody or antibody fragment binds specifically to the phosphorylcholine moiety in the phosphorylcholine conjugate.

23. A pharmaceutical composition comprising or consisting essentially of an antibody or an antibody fragment according to any of the preceding claims and a pharmaceutically acceptable carrier or excipient, optionally wherein the only antibodies or antibody fragments present in the composition are those defined by any of the preceding claims.

24. An antibody or antibody fragment according to any of Claims 1 to 22, or a pharmaceutical composition according to Claim 23 for use in medicine.

25. An antibody or antibody fragment according to any of Claims 1 to 22, or a pharmaceutical composition according to Claim 23 for use in the prevention, prophylaxis and/or treatment of mammals, including humans, against atherosclerosis, an atherosclerotic related disease or ischemic cardiovascular disease.

26. An antibody or antibody fragment according to any of Claims 1 to 22, or a pharmaceutical composition according to Claim 23 for use in the prophylaxis, prevention and/or treatment of Alzheimer's disease.

27. An antibody or antibody fragment according to any of Claims 1 to 22, or a pharmaceutical composition according to Claim 23 for use in the immunization or prophylaxis against, or the prevention or treatment of, metabolic diseases in mammals, including humans.

28. The antibody or antibody fragment according to any of Claims 1 to 22, or a pharmaceutical composition according to Claim 23 for use according to Claim 27, wherein the metabolic disease is a condition selected from the group consisting of metabolic syndrome, insulin resistance, glucose intolerance, hyperglycemia, type I diabetes, type II diabetes, hyperlipidemia,

hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and polycystic ovary syndrome (PCOS).

29. A nucleic acid sequences encoding an antibody or an antibody fragment according to any of Claims 1 to 22.

30. A vector or plasmid comprising the nucleic acid sequence of Claim 29.

31. A host cell comprising the nucleic acid sequence of Claim 29 and/or a vector or plasmid according to Claim 30.

32. The host cell of Claim 31 wherein the cell is a prokaryotic cell, such as an *Escherichia coli* cell, or a eukaryotic cell, such as animal, plant, or fungal cell.

33. The host cell of Claims 31 or 32 which expresses the nucleic acid sequence of Claim 29 and thereby produces an antibody or an antibody fragment according to any of Claims 1 to 22.

34. A method of producing an antibody or an antibody fragment according to any of Claims 1 to 22 comprising culturing a host cell according to Claim 33, and recovering therefrom an antibody or an antibody fragment according to any of Claims 1 to 22.

35. A method of preparing a variant of the antibody or antibody fragments of according to any of Claims 1 to 22, which variant retains the ability to bind to phosphorylcholine and/or a phosphorylcholine conjugate, the method comprising –

(i) providing a nucleic acid according to Claim 29 encoding a parent antibody or antibody fragment;

(ii) introducing one ore more nucleotide mutations into the amino acid coding regions of the nucleic acid sequence, optionally within the regions encoding the VH and/or VL domain(s), such that the mutated nucleic acid encodes a variant antibody or antibody fragment having a different amino acid sequence compared to the parent antibody or antibody fragment;

(iii) expressing the variant antibody or antibody fragment that is encoded by the mutated nucleic acid sequence; and

(iv) comparing the ability of the variant antibody or antibody fragment and the parent antibody or antibody fragment to bind to phosphorylcholine and/or a phosphorylcholine conjugate.

36. The method of Claim 35 wherein the step of assessing the ability of the variant antibody or antibody fragment to bind to phosphorylcholine and/or a phosphorylcholine conjugate further comprises selecting those variants that have substantially equal or enhanced ability to bind to phosphorylcholine and/or a phosphorylcholine conjugate compared to the parent.

37. The method of Claim 35 or 36 further comprising recovering a nucleic acid molecule that comprises the mutated nucleic acid sequence that encodes the variant antibody or antibody fragment, and optionally transforming a host cell with a composition comprising the recovered nucleic acid molecule and further optionally expressing the variant antibody or antibody fragment from the host cell, and yet further optionally recovering the thus-expressed variant antibody or antibody fragment from the host cell.

38. The method of Claim 37 that comprises the step of recovering the thus-expressed variant antibody or antibody fragment from the host cell, and further comprises the step of formulating the recovered variant antibody or antibody fragment into a pharmaceutically acceptable composition.

39. A variant antibody or antibody fragment obtained or obtainable by the method of Claim 35-37, or a pharmaceutically acceptable obtained or obtainable by the method of Claim 38 for use in medicine and/or for use in accordance with Claims 25, 26 and/or 27.

Claims

1. An antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein -

(a) the VH domain comprises an amino acid sequence that includes three complementarity determining regions (CDRs) selected from the group consisting of:

a CDR1 sequence comprising an amino acid sequence having at least 50%, 75% or 100% sequence identity to the sequence of SEQ ID NO: 17;

a CDR2 sequence comprising an amino acid sequence having at least 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 18; and

a CDR3 sequence comprising an amino acid sequence having at least 31%, 36%, 40%, 45%, 50%, 54%, 59%, 63%, 68%, 72%, 77%, 81%, 86%, 90%, 95% or 100% sequence identity to the sequence of SEQ ID NO: 19, 20, 21 or 22; and/or

(b) the VL domain comprises an amino acid sequence that includes three complementarity determining regions (CDRs) selected from the group consisting of:

a CDR4 sequence comprising an amino acid sequence having at least 82%, 94% or 100% sequence identity to the sequence of SEQ ID NO: 23 or 24;

a CDR5 sequence comprising an amino acid sequence having at least 71%, 85% or 100% sequence identity to the sequence of SEQ ID NO: 25;

a CDR6 sequence comprising an amino acid sequence having at least 77%, 88% or 100% sequence identity to the sequence of SEQ ID NO: 26.

2. The antibody or antibody fragment of Claim 1 wherein –

the VH domain comprises an amino acid sequence that includes the CDR1, CDR2 and CDR3 sequences present in an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15 or in an amino

acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence of any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15; and/or

the VL domain comprises an amino acid sequence that includes the CDR4, CDR5 and CDR6 sequences present in an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16 or in an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence of any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16.

3. An antibody or antibody fragment according to any preceding claim, wherein -

the VH domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15 or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence of any of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, or 15; and

the VL domain comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16 or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to an amino acid sequence of any of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, or 16.

4. The antibody or antibody fragment according to any of the preceding claims, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:1; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 2.

5. The antibody or antibody fragment according to any of Claims 1 to 3, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:3; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 4.

6. The antibody or antibody fragment according to any of Claims 1 to 3, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:5; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 6.

7. The antibody or antibody fragment according to any of Claims 1 to 3, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:7; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 8.

8. The antibody or antibody fragment according to any of Claims 1 to 3, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:9; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 10.

9. The antibody or antibody fragment according to any one of Claims 1 to 3, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:11; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 12.

10. The antibody or antibody fragment according to any one of Claims 1 to 3, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:13; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 14.

11. The antibody or antibody fragment according to any one of Claims 1 to 3, wherein -

the VH domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO:15; and

the VL domain comprises an amino acid sequence having at least 80%, 85%, 90%, 95% or 100% sequence identity SEQ ID NO: 16.

12. The antibody or antibody fragment according to any preceding claim, wherein the VH domain, the VL domain, or preferably both of the VH and VL domains, comprise an amino acid sequence having 100% sequence identity to the, or one or more of each, stated SEQ ID NO.

13. The antibody or antibody fragment according to any preceding claim, wherein the VH domain, the VL domain, or both of the VH and VL domains, comprise an amino acid sequence having less than 100%, but at least 80%, 85%, 90%, 95%, sequence identity to the, or one or more of each, stated SEQ ID NO.

14. The antibody or antibody fragment according to any of preceding claim, wherein the VH domain, the VL domain, or both of the VH and VL domains, comprise an amino acid sequence having less than 100%, but at least 80%, 85%, 90%, 95%, sequence identity to the, or one or more of each, stated SEQ ID NO, and wherein

the ability of the antibody or antibody fragment to bind to phosphorylcholine and/or a phosphorylcholine conjugate is equivalent to (that is, at least 80%, 85%, 90% or 95%, of), or greater than, the ability of a corresponding antibody or antibody fragment, wherein the VH domain and the VL domain of the corresponding antibody or antibody fragment each comprise an antigen-binding sequence comprising an amino acid sequence having 100% sequence identity to the, or each, stated SEQ ID NO.

15. The antibody or antibody fragment according to any preceding claim wherein the VH domain and the VL domain are present in a linear polypeptide sequence.

16. The antibody or antibody fragment according to any preceding claim wherein the VH domain and the VL domain are each present in a separate polypeptide sequence, and preferably wherein the separate polypeptide sequence are directly or indirectly bound together (such as by one or more disulphide bonds between the separate polypeptide sequence).

17. The antibody according to any of Claims 1-14 or 16 wherein the antibody is a monoclonal antibody.

18. The antibody fragment according to any of Claims 1 to 14 wherein the antibody fragment is a single chain antibody, Fv, scFv, Fab, $F(ab')_2$, Fab', Fd, dAb, CDR, or scFv-Fc fragment, a nanobody, and diabody, or any fragment that has been stabilized, optionally stabilized by PEGylation.

19. The antibody or antibody fragment according to any preceding claim which is a human or humanized antibody or antibody fragment, such as a human or humanized monoclonal antibody.

20. The antibody or antibody fragment according to any preceding claim which is capable of binding to a phosphorylcholine conjugate.

21. The antibody or antibody fragment according to Claim 20 wherein the phosphorylcholine conjugate is a phosphorylcholine moiety linked to a carrier, optionally via a spacer, and preferably the antibody or antibody fragment binds specifically to the phosphorylcholine moiety in the phosphorylcholine conjugate.

22. A pharmaceutical composition comprising or consisting essentially of an antibody or an antibody fragment according to any of the preceding claims and a pharmaceutically acceptable carrier or excipient, optionally wherein the only antibodies or antibody fragments present in the composition are those defined by any of the preceding claims.

23. An antibody or antibody fragment according to any of Claims 1 to 21, or a pharmaceutical composition according to Claim 22 for use in medicine.

24. An antibody or antibody fragment according to any of Claims 1 to 21, or a pharmaceutical composition according to Claim 22 for use in the prevention, prophylaxis and/or treatment of mammals, including humans, against atherosclerosis, an atherosclerotic related disease or cardiovascular disease.

25. The antibody or antibody fragment according to claim 24 wherein the cardiovascular disease is selected from the group consisting of atherosclerosis, acute coronary syndrome, acute myocardial infarction, myocardial infarction (heart attack), stable and unstable angina pectoris, aneurysms, coronary artery disease (CAD), ischemic heart disease, ischemic myocardium, cardiac and sudden cardiac

death, cardiomyopathy, congestive heart failure, heart failure, stenosis, peripheral arterial disease (PAD), intermittent claudication, critical limb ischemia, and stroke.

26. An antibody or antibody fragment according to any of Claims 1 to 21, or a pharmaceutical composition according to Claim 22 for use in the prophylaxis, prevention and/or treatment of Alzheimer's disease.

27. An antibody or antibody fragment according to any of Claims 1 to 21, or a pharmaceutical composition according to Claim 22 for use in the immunization or prophylaxis against, or the prevention or treatment of, metabolic diseases in mammals, including humans.

28. The antibody or antibody fragment according to any of Claims 1 to 21, or a pharmaceutical composition according to Claim 22 for use according to Claim 26, wherein the metabolic disease is a condition selected from the group consisting of metabolic syndrome, insulin resistance, glucose intolerance, hyperglycemia, type I diabetes, type II diabetes, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and polycystic ovary syndrome (PCOS).

29. A nucleic acid sequences encoding an antibody or an antibody fragment according to any of Claims 1 to 21.

30. A vector or plasmid comprising the nucleic acid sequence of Claim 29.

31. A host cell comprising the nucleic acid sequence of Claim 29 and/or a vector or plasmid according to Claim 30.

32. The host cell of Claim 31 wherein the cell is a prokaryotic cell, such as an *Escherichia coli* cell, or a eukaryotic cell, such as animal, plant, or fungal cell.

33. The host cell of Claims 31 or 32 which expresses the nucleic acid sequence of Claim 29 and thereby produces an antibody or an antibody fragment according to any of Claims 1 to 21.

34. A method of producing an antibody or an antibody fragment according to any of Claims 1 to 21 comprising culturing a host cell according to Claim 33, and

recovering therefrom an antibody or an antibody fragment according to any of Claims 1 to 21.

35. A method of preparing a variant of the antibody or antibody fragments of according to any of Claims 1 to 21, which variant retains the ability to bind to phosphorylcholine and/or a phosphorylcholine conjugate, the method comprising –

(i) providing a nucleic acid according to Claim 29 encoding a parent antibody or antibody fragment;

(ii) introducing one or more nucleotide mutations into the amino acid coding regions of the nucleic acid sequence, optionally within the regions encoding the VH and/or VL domain(s), such that the mutated nucleic acid encodes a variant antibody or antibody fragment having a different amino acid sequence compared to the parent antibody or antibody fragment;

(iii) expressing the variant antibody or antibody fragment that is encoded by the mutated nucleic acid sequence; and

(iv) comparing the ability of the variant antibody or antibody fragment and the parent antibody or antibody fragment to bind to phosphorylcholine and/or a phosphorylcholine conjugate.

36. The method of Claim 35 wherein the step of assessing the ability of the variant antibody or antibody fragment to bind to phosphorylcholine and/or a phosphorylcholine conjugate further comprises selecting those variants that have substantially equal or enhanced ability to bind to phosphorylcholine and/or a phosphorylcholine conjugate compared to the parent.

37. The method of Claim 35 or 36 further comprising recovering a nucleic acid molecule that comprises the mutated nucleic acid sequence that encodes the variant antibody or antibody fragment, and optionally transforming a host cell with a composition comprising the recovered nucleic acid molecule and further optionally expressing the variant antibody or antibody fragment from the host cell, and yet further optionally recovering the thus-expressed variant antibody or antibody fragment from the host cell.

38. The method of Claim 37 that comprises the step of recovering the thus-expressed variant antibody or antibody fragment from the host cell, and further

comprises the step of formulating the recovered variant antibody or antibody fragment into a pharmaceutically acceptable composition.

39. A variant antibody or antibody fragment obtained or obtainable by the method of Claim 35-37, which variant retains the ability to bind to phosphorylcholine and/or a phosphorylcholine conjugate, or a pharmaceutically acceptable composition obtained or obtainable by the method of Claim 38 for use in medicine and/or for use in accordance with Claims 24, 25, 26 and/or 27.